[1]Patent:WO2006/82392,2006,A1.Locationinpatent:Page/Pagecolumn86
[1]Locationinpatent:schemeortableWang,Tao;Ioannidis,Stephanos;Almeida,Lynsie;Block,MichaelH.;Davies,AudreyM.;Lamb,MichelleL.;Scott,DavidA.;Su,Mei;Zhang,Hai-Jun;Alimzhanov,Marat;Bebernitz,Geraldine;Bell,Kirsten;Zinda,Michael[BioorganicandMedicinalChemistryLetters,2011,vol.21,#10,p.2958-2961]
Title: Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.
Journal: International journal of cancer 20111115
Title: In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20110515
Title: AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
Journal: Molecular cancer therapeutics 20101201
Title: Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.
Journal: The Journal of biological chemistry 20081121
Title: Ikezoe T, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011 Nov 15;129(10):2512-21.
Title: Gozgit JM, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43.
Title: Yang J, et al. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther. 2010 Dec;9(12):3386-95.
Title: Valenciano AL, et al. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Bioorg Med Chem. 2016 Oct 1;24(19):4647-51.
